Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Petitou

Showing results (71-80 of 112) with videos related to

Pageof 12
Sort By:
Thrombosis Research|May 1, 1980
Anti-Xa active heparin oligosaccharidesJ Choay, J C Lormeau, M Petitou, et al.
Biochimie|August 1, 1990
Antithrombin III: structural and functional aspectsL Mourey, J P Samama, M Delarue, et al.
Bioorganic & Medicinal Chemistry Letters|May 18, 1999
Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimeticsM Petitou, P A Driguez, P Duchaussoy, et al.
Thrombosis and Haemostasis|September 28, 2002
The structure of synthetic oligosaccharides in relation to factor IXa inhibitionJ P Hérault, C Gaich, F Bono, et al.
Journal of Thrombosis and Haemostasis : JTH|August 28, 2003
Comparative effects of two synthetic oligosaccharides on platelet activation induced by plasma from HIT patientsP Savi, A-M Pflieger, J-P Hérault, et al.
Experimental Parasitology|July 1, 1990
Leishmania donovani: cell-surface heparin receptors of promastigotes are recruited from an internal pool after trypsinizationB A Butcher, K Shome, L W Estes, et al.
The Journal of Laboratory and Clinical Medicine|February 1, 1992
Pharmacologic properties of an unfractionated heparin butyryl derivative with long-lasting effectsS Saivin, M Petitou, J C Lormeau, et al.
European Journal of Clinical Pharmacology|October 16, 2016
Neutralization of EP217609, a new dual-action FIIa/FXa anticoagulant, by its specific antidote avidin: a phase I studyP Gueret, S Combe, C Krezel, et al.
Annales Pharmaceutiques Francaises|July 31, 1999
[New antithrombotic oligosaccharides]M Petitou, J P Hérault, A Bernat, et al.
Thrombosis Research|October 15, 1988
Effects of increased sulfation of dermatan sulfate on its in vitro and in vivo pharmacological propertiesF Dol, C Caranobe, D Dupouy, et al.
Pageof 12

Showing results (71-80 of 112) with videos related to

Sort By:
Pageof 12
Thrombosis Research|May 1, 1980
Anti-Xa active heparin oligosaccharidesJ Choay, J C Lormeau, M Petitou, et al.
Biochimie|August 1, 1990
Antithrombin III: structural and functional aspectsL Mourey, J P Samama, M Delarue, et al.
Bioorganic & Medicinal Chemistry Letters|May 18, 1999
Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimeticsM Petitou, P A Driguez, P Duchaussoy, et al.
Thrombosis and Haemostasis|September 28, 2002
The structure of synthetic oligosaccharides in relation to factor IXa inhibitionJ P Hérault, C Gaich, F Bono, et al.
Journal of Thrombosis and Haemostasis : JTH|August 28, 2003
Comparative effects of two synthetic oligosaccharides on platelet activation induced by plasma from HIT patientsP Savi, A-M Pflieger, J-P Hérault, et al.
Experimental Parasitology|July 1, 1990
Leishmania donovani: cell-surface heparin receptors of promastigotes are recruited from an internal pool after trypsinizationB A Butcher, K Shome, L W Estes, et al.
The Journal of Laboratory and Clinical Medicine|February 1, 1992
Pharmacologic properties of an unfractionated heparin butyryl derivative with long-lasting effectsS Saivin, M Petitou, J C Lormeau, et al.
European Journal of Clinical Pharmacology|October 16, 2016
Neutralization of EP217609, a new dual-action FIIa/FXa anticoagulant, by its specific antidote avidin: a phase I studyP Gueret, S Combe, C Krezel, et al.
Annales Pharmaceutiques Francaises|July 31, 1999
[New antithrombotic oligosaccharides]M Petitou, J P Hérault, A Bernat, et al.
Thrombosis Research|October 15, 1988
Effects of increased sulfation of dermatan sulfate on its in vitro and in vivo pharmacological propertiesF Dol, C Caranobe, D Dupouy, et al.
Pageof 12